Tony Tipton serves as Chief Operating Officer and is responsible for Xequel Bio’s Corporate Development and Licensing, Commercial Operations, Asset Reimbursement Strategies, and Pre-Launch Commercial activities. Focused priorities encompass external corporate relationships with potential business partners, in-licensing, out-licensing, asset evaluations in the areas of reimbursement and market value, partnering with the Xequel Bio clinical teams in mining core technologies for innovative high-value marketable assets that solve unmet clinical treatment needs, as well as team and organizational leadership.
Prior to joining Xequel, Tony served as Vice President of Market Access and Trade Channels at Santen Pharmaceuticals, USA, formerly Eyevance Pharmaceuticals. He brings over twenty-five years of specialty biopharma executive leadership experience in developing and executing business strategies across market access, trade distribution, commercial sales and marketing, business development and organizational growth. Tony’s past roles in biopharma have provided diversified experiences in numerous specialty areas including Dermatology, Neurology, Ophthalmology, Psychiatry, and Respiratory diseases.
The unlimited potential of Xequel Bio is the primary driver of Tony’s excitement about the organization. The synergy between the leadership team and the talented scientists, coupled with the aCT1 technology platform, position Xequel to offer highly-valued products for providers and patients. Tony’s personal interests are founded on family time. In addition to enjoying time with his wife and two sons, he enjoys golfing, running, and DIY home projects. He looks forward to more travel and adventures for he and his wife, Kathy, over the next few years.